These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

986 related items for PubMed ID: 15287092

  • 41. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 42. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 Feb 15; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 43. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 44. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
    Gong B, Almasan A.
    Cancer Res; 2000 Oct 15; 60(20):5754-60. PubMed ID: 11059770
    [Abstract] [Full Text] [Related]

  • 45. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 15; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 46. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
    Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS.
    Oncogene; 2003 Aug 07; 22(32):4953-63. PubMed ID: 12902978
    [Abstract] [Full Text] [Related]

  • 47. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
    Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS, Pour PM.
    Clin Cancer Res; 2001 Feb 07; 7(2):407-14. PubMed ID: 11234897
    [Abstract] [Full Text] [Related]

  • 48. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS, Kemp TJ.
    Cancer Chemother Pharmacol; 2003 Sep 07; 52(3):175-84. PubMed ID: 12811515
    [Abstract] [Full Text] [Related]

  • 49. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C, King DL, Norris JS.
    Cancer Gene Ther; 2002 Feb 07; 9(2):164-72. PubMed ID: 11857034
    [Abstract] [Full Text] [Related]

  • 50. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA.
    Cancer Res; 2005 Aug 15; 65(16):7436-45. PubMed ID: 16103097
    [Abstract] [Full Text] [Related]

  • 51. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM.
    Cancer Res; 2003 Jun 15; 63(12):3112-20. PubMed ID: 12810637
    [Abstract] [Full Text] [Related]

  • 52. Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: evidence for multiple sites of interactions.
    Cantarella G, Risuglia N, Lombardo G, Lempereur L, Nicoletti F, Memo M, Bernardini R.
    Cell Death Differ; 2004 May 15; 11(5):503-11. PubMed ID: 14739940
    [Abstract] [Full Text] [Related]

  • 53. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ.
    Gene Ther; 2004 Apr 15; 11(8):658-67. PubMed ID: 14973547
    [Abstract] [Full Text] [Related]

  • 54. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF, Erff M, Ashkenazi A.
    Clin Cancer Res; 2001 May 15; 7(5):1362-9. PubMed ID: 11350907
    [Abstract] [Full Text] [Related]

  • 55. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
    Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM.
    Oncogene; 2005 Sep 01; 24(38):5868-77. PubMed ID: 15897871
    [Abstract] [Full Text] [Related]

  • 56. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.
    Cancer Res; 2004 Oct 01; 64(19):7086-91. PubMed ID: 15466204
    [Abstract] [Full Text] [Related]

  • 57. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 58. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 59. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, Chang JW, Oh W, Jeun SS.
    Stem Cells; 2010 Dec 01; 28(12):2217-28. PubMed ID: 20945331
    [Abstract] [Full Text] [Related]

  • 60. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.
    Hahm ER, Arlotti JA, Marynowski SW, Singh SV.
    Clin Cancer Res; 2008 Feb 15; 14(4):1248-57. PubMed ID: 18281560
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.